Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine added to second generation antipsychotics in schizophrenia
IRCT2015041521779N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Second generation antipsychotic + pyridostigmine with Second generation antipsychotic + placebo (2 arms). Primary endpoint: Change in schizophrenia symptom severity. Started Jun 2015; status: completed.
02
Drugs
pyridostigmine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT2015041521779N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2015041521779N1.